Randomized trial · people
Tirzepatide: up to 17.5% weight loss at 52 weeks in SURMOUNT-CN
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In Chinese adults without diabetes, both the 10 mg and 15 mg arms of tirzepatide led to far more weight loss than placebo over a year, with gut side effects the most common problem.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 210
- Published
- 2024
- Journal
- JAMA
What they tested
The team tested whether weekly tirzepatide shots work and are safe for weight loss in Chinese adults with obesity, or overweight plus a weight-related health problem.
How the study was done
A randomized, double-blind, placebo-controlled phase 3 trial at 29 centers in China in 210 adults without diabetes, who had a BMI of 28 or more, or 24 or more with at least 1 weight-related condition. For 52 weeks they got weekly injections of tirzepatide 10 mg (70 people), 15 mg (71 people) or placebo, a dummy shot (69 people), plus a lifestyle program.

Model. Individual results vary.
What they found
At week 52, average body weight fell 13.6% in the 10 mg arm and 17.5% in the 15 mg arm, compared with 2.3% on placebo. Compared with placebo, the difference was -11.3% for 10 mg and -15.1% for 15 mg, and both differences were statistically significant. A weight loss of at least 5% was reached by 87.7% in the 10 mg arm, 85.8% in the 15 mg arm and 29.3% on placebo. Stomach and gut side effects were the most common with tirzepatide, mostly mild to moderate, and fewer than 5% of events led people to stop treatment.
What it doesn’t show
The trial ran for 52 weeks in about 70 people per group, all Chinese adults, and people with diabetes were left out. It does not show what happens after a year or in other groups.
The paper
Zhao et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024.
The compound
More studies on Tirzepatide
- Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZERandomized trial · people · 2026
- Dulaglutide: switching to tirzepatide beat dose escalation on HbA1cRandomized trial · people · 2025
- Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: about 75% of weight lost was fat in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: most reached a weight plateau by week 72 in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: 20.2% weight loss vs 13.7% on semaglutide at 72 weeksRandomized trial · people · 2025
- Every study on Tirzepatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.